• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Mark McCamish - Articles and news items

Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®

Industry news / 8 December 2014 / Novartis

Sandoz, a Novartis company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen’s NEUPOGEN ® (filgrastim) in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy…

Sandoz launches Phase III clinical trial for biosimilar etanercept

Industry news, News / 24 June 2013 / Novartis

Sandoz has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen’s Enbrel®)…